Lawrence J. Singerman, MD, recently returned from Denver, Colorado, where he presented research findings at the 2015 Association for Research in Vision and Ophthalmology (ARVO) meeting. ARVO is one of the largest gatherings of eye and vision researchers in the world, attracting over 11,000 attendees from more than 75 countries. Dr. Singerman presented research results from the OSPREY trial, the Squalamine eye drops study, and a CFH and ARMS2 genetic polymorphisms study.
The OSPREY study is a randomized, active-controlled study to evaluate the safety and efficacy of RTH258, a humanized single-chain anti-VEGF antibody fragment developed to treat patients with neovascular age-related macular degeneration (wet AMD). It is currently a Phase III trial. The Squalamine study is also in Phase III and is evaluating the use of squalamine eye drops 0.2% (OHR-102) in the treatment of wet AMD. Dr. Singerman's 3rd presentation on CFH and ARMS2 examined results from the Phase II study to evaluate the prevalence of CFH and ARMS2 (genetic polymorphisms) in African-American patients with age-related macular degeneration.